Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

@article{Sanchez2012SerumBM,
  title={Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival},
  author={Eric Sanchez and Mingjie Li and Alex Kitto and Jennifer S. Li and Cathy S. Wang and Dylan T. Kirk and Ori Yellin and Cydney Nichols and Marissa P Dreyer and Cameryn P Ahles and Austin Robinson and Erik K. Madden and Gabriel N. Waterman and Regina Swift and Benjamin Bonavida and Ralph V. Boccia and Robert A. Vescio and John Crowley and Haiming Chen and James R. Berenson},
  journal={British Journal of Haematology},
  year={2012},
  volume={158}
}
Although TNFRSF17 (also designated as B‐cell maturation antigen (BCMA)) is expressed on tumour cells in B‐cell malignancies, it has not been found in serum. The present study found that BCMA concentrations were higher in the supernatants of cultured bone marrow mononuclear cells from multiple myeloma (MM) patients than in healthy subjects. Serum BCMA levels were measured in samples from MM patients (n = 209), monoclonal gammopathy of undetermined significance (MGUS) individuals (n = 23) and age… Expand
Normalization of serum B‐cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment
TLDR
It is found that among multiple myeloma patients starting a new treatment, those who begin treatment within normal sBCMA limits have improved progression‐free survival (PFS) and overall survival (OS) than those who do not and normalization of s BCMA may be an accurate predictor of OS for MM patients during treatment. Expand
Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia
TLDR
PBCMA is a promising new prognostic and predictive indicator for patients with CLL and changes in these levels correlated with changes in their clinical status. Expand
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
TLDR
Serum B-cell maturation antigen levels did not show any dependence on renal function and maintained independent significance when tested against other known prognostic markers for multiple myeloma such as age, serum β2 microglobulin, hemoglobin, and bone disease. Expand
Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.
TLDR
It is demonstrated that circulating BCMA levels in most RRMM patients are high enough to interfere with anti-BCMA antibody binding to MM tumor cells and may interfere with BCMA-targeted immune-based therapies. Expand
Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy
TLDR
The results indicate the potential for the use of sBCMA as a new biomarker for monitoring patients with multiple myeloma starting new treatments and suggest it has the potential to improve progression-free survival and overall survival. Expand
Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance
TLDR
For the gene and protein expression of BAFF and APRIL in patients with multiple myeloma, the initial treatment group and non-remission are higher than control and remission group. Expand
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
TLDR
Preclinical and clinical data of current BCMA-targeted immunotherapies with various mechanisms of action are highlighted and crucial studies will enhance selective anti-MM response, transform the treatment paradigm, and extend disease-free survival in MM. Expand
The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker
TLDR
This BCMA review encompasses full-text publications of original research articles and abstracts presented at hematology/oncology meetings and shows great promise for BCMA-directed therapies with promising clinical results. Expand
Anti-BCMA antibodies in the future management of multiple myeloma
TLDR
This review aims to present the mechanisms of action and the available data on efficacy and safety of therapies targeting BCMA, a novel prognostic and monitoring tool in patients with multiple myeloma and chronic lymphocytic leukemia. Expand
Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients
TLDR
The receptor sBCMA could be a potential biomarker of disease activity in SLE patients andSoluble levels of the receptor s BCMA and its ligands sAPRIL and sBAFF were increased in Sle patients compared with HCs, and correlated strongly with disease activity. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 67 REFERENCES
Serum BLyS Level as a Prognostic Marker in Patients with Lymphoma.
TLDR
Serum BLyS level is particularly higher in patients with relapsed disease, and is associated with poor prognosis in those patients group, suggesting the promising role of BLs in the prognostication of patients with lymphoma, particularly aggressive NHL and HL. Expand
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.
TLDR
Evidence that B-lymphocyte stimulator (BLyS) can modulate the proliferative capacity and survival of MM cells is provided and evidence that BLyS is expressed by MM cells and is present in the bone marrow of patients with MM. Expand
A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
TLDR
Initial staging can be quantitatively related to followup using tumor cell mass changes calculated from changes in M‐component production, and should lead to improved study design and analysis in large clinical trials of therapy for multiple myeloma. Expand
Antibody targeting of B-cell maturation antigen on malignant plasma cells
TLDR
B-cell maturation antigen (BCMA) antibodies show cytotoxic activity both as naked IgG and as drug conjugates and warrant further evaluation as therapeutic candidates for plasma cell malignancies. Expand
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.
TLDR
It is demonstrated that B-cell maturation antigen (BCMA), a transmembrane receptor of the tumor necrosis factor (TNF) superfamily, is a target of donor B- cell immunity in patients with myeloma who respond to DLI. Expand
Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma.
TLDR
Serial measurements of tumor cell number may prove useful in characterizing the growth rate and natural history of multiple myeloma and could be correlated with the degree of skeletal damage observed on roentgenograms. Expand
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
TLDR
The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations to facilitate comparison of therapeutic trial data. Expand
B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia.
TLDR
The role of B-lymphocyte stimulator, alone or in combination with cytokines that induce immunoglobulin production, was found to increase IgM secretion by malignant B cells and BLyS was finding to increase the viability and proliferation of malignant b cells from WM patients. Expand
Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.
TLDR
BLyS may be an important factor in driving polyclonal hypergammaglobulinemia and elevated autoantibody titers in patients with systemic immune-based rheumatic diseases. Expand
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
TLDR
These findings demonstrate the involvement of zTNF4 and its receptors in the development of SLE and identify TACI–Ig as a promising treatment of autoimmune disease in humans. Expand
...
1
2
3
4
5
...